P3563 - Trends and Outcomes of Crohn's Diseases in Patients with Diabetes Mellitus: A Propensity Score Matching Analysis

Ese Uwagbale, MD¹, Olayemi Adeniran, MD², Samrah Siddiqui, MD², Zhanna Zavgorodneva, MD³, Rutwik Pradeep Sharma, MD⁴, Chidiebele Omaliko, MD⁵, Solomon Agbroko, MD⁶, Dileepa Chathuranga, MD¹, Nida Khalid, MD¹, Dasha Moza, MD¹, Karin Dunnigan, MD¹, Patrick Okolo, MD, MPH, FACG^1
1Rochester General Hospital, Rochester, NY; ²One Brooklyn Health, Brooklyn, NY; ³One Brookyln Health, Brooklyn, NY; ⁴Rochester Regional Health / Unity Hospital, Rochester, NY; ⁵One Brooklyn Health-Brookdale University Hospital Medical Center, Brooklyn, NY; ⁶Maimonides Medical Center, Brooklyn, NY

Introduction: Crohn's disease is a type of inflammatory bowel disease. Crohn's disease (CD) patients often have other comorbidities, including diabetes mellitus (DM). However, there are very few studies on the effect of comorbid DM in patients with CD. This study aims to examine the clinical outcomes of hospitalized patients with CD and DM.

Methods: We analyzed the National Inpatient Sample (NIS) database from January 1, 2016, to December 31, 2020. Patients aged 18 years and older with primary and secondary diagnoses of CD were identified. The study population was further categorized into patients with comorbid diabetes mellitus (CD DM) and those without diabetes (non-DM). Primary outcomes were in-hospital mortality, CD-related complications, CD-related surgery, septicemia, Clostridium difficile infection, and colorectal cancer. Secondary outcomes included resource utilization measures: length of stay and cost of hospitalizations. Propensity score matching (PSM) was performed to control confounding factors.

Results: Of the 190,148 patients who met the inclusion criteria, 32,306 were included in the DM group and 157,842 in the non-DM group. Overall, there were no significant changes in hospitalizations and in-hospital mortality of CD and subgroups (DM and non-DM) between 2016 and 2020. Patients in the DM group were likely to be older and had a higher prevalence of comorbidities. After PSM, we obtained a well-balanced cohort of 31,981 DM matched to 31,981 non-DM groups, and the outcomes were compared. Patients in the DM group were more likely to have an increased prevalence of sepsis/septicemia (10.5% vs. 14.1%, OR=0.23, CI: 0.08-0.64; p< 0.001) and depression (10.5% vs. 14.1%, OR=0.23, CI: 0.08-0.64; p< 0.001). There was no significant difference in the prevalence of clostridium difficile infections, colorectal cancer, in-hospital mortality, length of stay, and cost of hospitalizations among the two cohorts. DM cohort had lower CD-related complications (10.5% vs. 14.1%, OR = 0.23, CI: 0.08-0.64; p< 0.001), intestinal surgeries (17.8% vs. 20.9%, OR=0.23, CI: 0.08-0.64; p< 0.001), anxiety (21.0% vs. 21.7%, OR=0.23, CI: 0.08-0.64; p=0.0241), and the overall major adverse events (32.6% vs. 35.6%, OR=0.23, CI: 0.08-0.64;p< 0.001).

Discussion: Patients with CD and DM have an increased rate of sepsis and septicemia compared to patients with Crohn's disease without diabetes. The severity of Crohn's disease and diabetes was, however, not examined in this study.



Disclosures:


Ese Uwagbale, MD¹, Olayemi Adeniran, MD², Samrah Siddiqui, MD², Zhanna Zavgorodneva, MD³, Rutwik Pradeep Sharma, MD⁴, Chidiebele Omaliko, MD⁵, Solomon Agbroko, MD⁶, Dileepa Chathuranga, MD¹, Nida Khalid, MD¹, Dasha Moza, MD¹, Karin Dunnigan, MD¹, Patrick Okolo, MD, MPH, FACG¹. P3563 - Trends and Outcomes of Crohn's Diseases in Patients with Diabetes Mellitus: A Propensity Score Matching Analysis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.